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Abstract
Osteoarthritis (OA), the commonest form of arthritis and a major
cause of morbidity, is characterized by progressive
degeneration of the articular cartilage. Along with increased
production and activation of degradative enzymes, altered
synthesis of cartilage matrix molecules and growth factors by
resident chondrocytes is believed to play a central role in this
pathological process. We used an ovine meniscectomy model
of OA to evaluate changes in chondrocyte expression of types I,
II and III collagen; aggrecan; the small leucine-rich
proteoglycans (SLRPs) biglycan, decorin, lumican and
fibromodulin; transforming growth factor-β ; and connective
tissue growth factor. Changes were evaluated separately in the
medial and lateral tibial plateaux, and were confirmed for
selected molecules using immunohistochemistry and Western
blotting. Significant changes in mRNA levels were confined to
the lateral compartment, where active cartilage degeneration
was observed. In this region there was significant upregulation
in expession of types I, II and III collagen, aggrecan, biglycan and
lumican, concomitant with downregulation of decorin and
connective tissue growth factor. The increases in type I and III
collagen mRNA were accompanied by increased
immunostaining for these proteins in cartilage. The upregulated
lumican expression in degenerative cartilage was associated
with increased lumican core protein deficient in keratan sulphate
side-chains. Furthermore, there was evidence of significant
fragmentation of SLRPs in both normal and arthritic tissue, with
specific catabolites of biglycan and fibromodulin identified only
in the cartilage from meniscectomized joints. This study
highlights the focal nature of the degenerative changes that
occur in OA cartilage and suggests that altered synthesis and
proteolysis of SLRPs may play an important role in cartilage
destruction in arthritis.
Introduction
Articular cartilage exhibits unique hydrodynamic and viscoe-
lastic properties that are largely attributable to its extracellular
matrix (ECM), which equips diarthrodial joints with their
weight-bearing properties and near frictionless articulation.
Cartilage ECM is composed of a collagen network, predomi-
nantly type II, in which large chondroitin sulphate and keratan
sulphate (KS) substituted proteoglycans (aggrecan) are
entrapped. The negatively charged aggrecan glycosaminogly-
can side-chains act to create an osmotic swelling pressure in
the cartilage matrix that is resisted by tension developed in the
collagen network [1]. The generation of a hydrostatic pressure
within cartilage allows it to counteract the loads transmitted to
it from the long bones during normal joint articulation.
CTGF = connective tissue growth factor; ECM = extracellular matrix; KS = keratan sulphate; LTP = lateral tibial plateau; MTP = medial tibial plateau; 
OA = osteoarthritis; RT-PCR = reverse transcription polymerase chain reaction; SLRP = small leucine-rich proteoglycan; TGF = transforming growth 
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The ECM of cartilage also contains the small leucine-rich pro-
teoglycans (SLRPs) biglycan, decorin, fibromodulin and lumi-
can, which have diverse functions as modulators of tissue
organization, cellular proliferation, adhesion and responses to
growth factors and cytokines [2,3]. The SLRPs all bind to fibril-
lar type I and/or II collagens [4-6] and, in the case of decorin,
to fibromodulin and lumican; these interactions modulate the
rate and ultimate diameter of collagen fibrils formed in vitro [7-
9]. Decorin, biglycan and fibromodulin can also form com-
plexes with transforming growth factor (TGF)-β  and modulate
the action of this growth factor [10,11]. The physical presence
of the SLRPs, in addition to the minor type IX and XI collagens,
on the surface of type II collagen fibrils has been proposed to
restrict sterically the access of collagenases to sites of cleav-
age on the collagen fibrils [12]. Complexes of matrilin-1 and
decorin or biglycan have also been reported to connect type
VI collagen to aggrecan and type II collagen, further stabilizing
the cartilage ECM [13]. It is evident that there is a complex
interplay between the collagenous and proteoglycan compo-
nents of the cartilage ECM that produces a biocomposite
material with unique mechanical properties. Disruption of the
normal balance of ECM components through altered synthesis
or degradation will have important ramifications for the load-
bearing capacity of cartilage.
Chondrocytes, the highly differentiated cells of cartilage, are
responsible for maintaining a homeostatic balance between
production and degradation of cartilage ECM [14,15]. The
metabolic status of the chondrocyte is central to our under-
standing of the initiation and progression of osteoarthrits (OA)
[16]. An initial anabolic response of chondrocytes in OA
includes an upregulation of mRNA levels for the major struc-
tural components type II collagen and aggrecan, with an asso-
ciated elevation in synthesis [17,18]. Degradation of the ECM
is also elevated in these early stages in OA. Eventually, the bio-
synthetic machinery of the chondrocyte is unable to keep up
with the anabolic demands and a net depletion of ECM occurs
during the later stages of OA. Loss of key functional compo-
nents combined with a disrupted architecture result in com-
promised tissue function, cell death and, eventually, cartilage
loss down to subchondral bone.
Changes in SLRP metabolism in human OA are relatively
poorly characterized, with both increased synthesis and deg-
radation of individual molecules reported in arthritic human
cartilage [19,20]. Their function within the collagen network
means that changes in their tissue content may significantly
alter the biomechanical integrity of cartilage. However,
because SLRPs are also regulators of growth factor activity,
changes in their synthesis and degradation may have signifi-
cant effects on chondrocyte metabolism. It is unclear whether
the changes in SLRP metabolism are restricted to the cartilage
undergoing OA degeneration or are more generalized within
arthritic joints. An understanding of the changes that occur
with the onset and progression of cartilage degeneration in
OA may provide important insights into potential regulatory
steps in this process.
Animal models of OA have permitted longitudinal evaluation of
spatial and temporal changes in joint tissues that occur during
the development of joint disease. Total or partial removal of
knee joint meniscus in humans commonly results in degenera-
tion of articular cartilage, leading to osteoarthritic changes
[21]. In sheep, lateral meniscectomy has been shown to relia-
bly reproduce biochemical, biomechanical and histopatholog-
ical alterations typical of OA [22,23]. In the present study we
used this established model of OA to study the changes in
expression of key structural molecules (aggrecan and type II
collagen), the collagen-associated SLRPs (biglycan, decorin,
lumican and fibromodulin), TGF-β 1 and its associated down-
stream signaling molecule connective tissue growth factor
(CTGF), and markers of altered chondrocyte phenotype –
types I and III collagen. The expression levels were compared
with protein levels in cartilage extracts or by immunohisto-
chemistry in tissues with various histopathological grades of
OA in the medial and lateral joint compartments.
Materials and methods
Animal model
Twelve 7-year-old female pure-bred Merino sheep were used
in the present study. Six of the sheep underwent open lateral
meniscectomy of both stifle joints, as previously described
[24], whereas the remaining six served as nonoperated con-
trols. Following recovery from surgery, the animals were main-
tained in an open paddock for 6 months before sacrifice. The
protocol used for the present study was approved by the ani-
mal ethics committee of Murdoch University, Western Aus-
tralia (AEC 832R/00).
Tissue preparation
Full depth articular cartilage from the medial tibial plateau
(MTP) and lateral tibial plateau (LTP) was sampled from either
the right or left stifle (knee) joint, randomly selected. Care was
taken not to sample tissue from the joint margins or osteo-
phytes. Tissue samples were snap frozen in liquid nitrogen
before storage at -80°C until they were required. The tibial pla-
teaux from the contralateral joints were isolated by a horizontal
cut through the tibia below the epiphyseal growth plate using
a band saw. Full thickness coronal osteochondral slabs (5
mm) were subsequently prepared through the mid weight-
bearing region of the tibial plateau.
Histology
The coronal tibial osteochondral slices were fixed in 10% (vol/
vol) neutral buffered formalin for 48 hours then decalcified in
10% formic acid (vol/vol)/5% formalin (vol/vol) for 5 days. The
specimens were then dehydrated in graded alcohols and dou-
ble-embedded in celloidin–paraffin blocks. Tissue sections (4
µm) were cut using a rotary microtome and attached to micro-
scope slides. They were then deparaffinized in xylene andAvailable online http://arthritis-research.com/content/7/4/R852
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washed in graded alcohols to 70% (vol/vol) ethanol and then
stained for 10 min with 0.04% (weight/vol) toluidine blue in
0.1 mol/l sodium acetate buffer (pH 4.0) to visualize the tissue
proteoglycans. This was followed by 2 min counter-staining in
an aqueous 0.1% (weight/vol) Food Drug and Cosmetic
Green Nos. 3 stain. The slides were subsequently evaluated
by bright field microscopy using a Leica MPS-60 (Leica Micro-
systems, Gladesville, New South Wales, Australia) photomi-
croscope system by two independent observers using a
modified Mankin scoring scheme, previously developed in our
laboratory for this ovine model [22]. In each compartment the
worst score evident across the width of the tibial plateau was
used to calculate the mean score for MTP and LTP of control
and meniscectomized joints (n = 6 for each group).
Immunohistochemistry
Immunostaining was performed using monoclonal antibodies
against type I collagen (ICN Biomedicals, Aurora, USA; code
no. 63170; clone no. I-8H5) and type II collagen (ICN Biomed-
icals, North Ryde, New South Wales, Australia; code no.
63171; clone no. II-4CII), and a polyclonal antibody against
type III collagen (Cedarlane, Hornby, Ontario, Canada; code
no. CL50321AP). Endogenous peroxidase activity was initially
blocked by incubating the tissue sections in 3% (vol/vol) H2O2
for 5 min and the sections were rinsed in TBS-Tween.
For type I and II collagen localizations, the sections were pre-
digested with proteinase K (Dako, Glostrup, Denmark; code
no. S3020) for 6 min at room temperature, followed by bovine
testicular hyaluronidase (Sigma, St Louis, MO, USA; code no.
H-3506) 1000 U/ml for 1 hour at 37°C in phosphate buffer
(pH 5.0). The type III collagen localizations were predigested
with hyaluronidase alone. The sections were then incubated in
10% (vol/vol) swine serum for 10 min at room temperature to
block any nonspecific binding.
Incubations with the primary antibodies were performed over-
night at 4°C with type I (5 µg/ml), type II (10 µg/ml) and type
III (1:500 dilution) collagens. Detection of primary antibody
was undertaken using a 20 min incubation with a cocktail of
biotinylated anti-rabbit and anti-mouse immunoglobulin sec-
ondary antibodies (Dako; code no. K1015), followed by a 20
min incubation with streptavidin-conjugated horseradish per-
oxidase (Dako; code no. K0690). Staining was undertaken
using NovaRED substrate (Vector, Burlingame, CA, USA;
code no. SK-4800) for 15 min, which gives a red–brown end
product. Sections were counter-stained in Mayer's haematox-
ylin for 1 min, washed in H2O, dehydrated in ethanol, cleared
in xylene and mounted. Negative control sections were pre-
pared using irrelevant isotype matched primary antibodies
(Dako; code no. X931 or X0936) in place of authentic primary
antibody.
RNA extraction
Approximately 100 mg of frozen cartilage samples was frag-
mented in a Mikro-Dismembrator (Braun Biotech International,
Melsungen, Germany), 1 ml of TRIzol Reagent (Invitrogen Life
Technologies, Carlsbad, CA, USA) was added, and the mix-
ture was allowed to defrost to room temperature. Total RNA
was isolated using the RNeasy Mini Kit from Qiagen (Valencia,
CA, USA). Chloroform (300 µl) was subsequently added to
the samples and the tubes vortexed vigorously before centrif-
ugation to pellet the tissue residue. The clear supernatant
solution (aqueous phase) was recovered and mixed by inver-
sion with an equal volume of 70% ethanol, and then loaded
onto spin columns. Following several washing steps and an
on-column DNase digestion (Qiagen, Hilden, Germany), RNA
was eluted from the column with 32 µl of RNAse free distilled
H2O. Total RNA was quantified using a flourimeter (Perkin
Elmer, Beaconsfield, UK) using SYBR® Green II colour rea-
gent (Cambrex Bio Science, Rockland, ME, USA), and each
sample was assessed for purity to confirm the absence of
detectable DNA.
Semiquantitative RT-PCR
RT reactions were undertaken with 1 µg total RNA using the
Omniscript RT kit from Qiagen (Germany). Using specific
primer sets (Sigma Genosys, Castle Hill, New South Wales,
Australia; Table 1), aliquots of cDNA were amplified by PCR,
with initial denaturation at 94°C for 5 min, followed by cycles
of 30 s of denaturation at 94°C, 30 s annealing at variable
primer specific temperatures (Table 1), 30 s for extension at
72°C, and a further 7 min extension at 72°C on completion of
the cycles. Reactions generated single PCR products that
were identified by sequencing (SUPAMAC, Sydney, Australia)
and specificity confirmed by BLAST searches. Cycle optimiza-
tion was performed for each primer set before PCR, and for all
reported experiments amplification levels were compared in
the linear range of the PCR reaction. All samples underwent
RT and cDNA amplification at the same time to avoid potential
variations in experimental conditions.
The amplified products were electrophoresed on 2% (weight/
vol) agarose gels, stained with ethidium bromide, imaged
using a Fujifilm FLA-3000 fluorescent image analyzer and inte-
grated densities calculated using One-Dscan, 1-D gel analysis
software (Scanalytics, Fairfax, VA, USA). Sample loadings
were normalized to the housekeeping gene GAPDH (glyceral-
dehyde-3-phosphate dehydrogenase) to permit semiquantita-
tive comparisons in mRNA levels, as previously described
[25,26].
Cartilage extraction, SDS-PAGE and Western blotting of 
the small leucine-rich proteoglycans
Pooled cartilage samples from all meniscectomized and non-
operated control LTPs were finely diced and extracted with 10
volumes of 4 mol/l GuCl and 50 mmol/l Tris HCl (pH 7.2) in
the presence of proteinase inhibitors at 4°C with end over endArthritis Research & Therapy    Vol 7 No 4    Young et al.
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stirring for 48 hours before dialysis of the extract against
ultrapure water, as described previously [27]. Insufficient car-
tilage was available from MTPs for extraction and Western blot
analyses. Dialysed extracts corresponding to equal dry
weights of tissue were predigested with either chondroitinase
ABC (Seikagaku) 0.1 U/ml alone or in combination with kera-
tanase II (Seikagaku) 0.01 U/ml and endo-β -galactosidase
(Seikagaku, Tokyo, Japan) 0.01 U/ml in 0.1 mol/l Tris/0.1 mol/
l sodium acetate (pH 7.0) overnight at 37°C before electro-
phoresis. Electrophoresis was conducted under reducing
conditions in 10% NuPAGE Bis-Tris resolving gels (Invitro-
gen), using MOPS SDS running buffer at 125 V constant volt-
age for 1 hour. The gels were then electroblotted to
nitrocellulose membranes in NuPAGE transfer buffer with
20% (vol/vol) methanol at 200 mA for 2 hours and blocked
overnight in 5% (weight/vol) BSA in 50 mmol/l Tris-HCl (pH
7.2) and 0.15 mol/l NaCl 0.02% (weight/vol) NaN3 (TBS-
azide). The blots were probed overnight with affinity purified
polyclonal antibodies directed against the carboxyl-terminus of
decorin, biglycan, fibromodulin and lumican (0.3–1 µg/ml)
[12] followed by washing in TBS-azide and detection using
alkaline phosphatase conjugated anti-rabbit secondary anti-
bodies and the nitro blue tetrazolium/4-bromo-1-chloro-indolyl
phosphate substrate system (BioRad, Hercules, CA, USA). A
sample of human OA cartilage harvested from the tibial pla-
teau at the time of joint replacement surgery also underwent
identical processing as a positive control.
Statistical analysis
All RT-PCR data were normalized to the housekeeping gene
GAPDH (glyceraldehyde-3-phosphate dehydrogenase) to
facilitate equal loading of gels for quantitative comparisons of
amplified PCR products. Comparison of parametric data from
the nonoperated and meniscectomized sample groups were
undertaken using the unpaired Student's t-test with Ben-
jamini–Hochberg correction [28] for multiple comparisons.
Comparisons of nonparametric data from the modified Mankin
histological scoring of the stained tissue sections were
assessed using the Mann–Whitney U-test.
Results
Histology
Lateral meniscectomy resulted in macroscopic joint changes
characteristic of the early and middle phases of OA with carti-
lage fibrillation and erosion, in addition to formation of marginal
osteophytes, particularly in the lateral compartment (Fig. 1f;
arrowheads). The histopathological lesions varied between
animals, between medial and lateral joint compartments, and
across the width of the tibial plateaux. A significant loss of pro-
teoglycan was evident in the superficial cartilage of both the
LTP (Fig. 1d, e) and, to a lesser extent, the MTP of the menis-
cectomized joints (Fig. 1b) compared with nonoperated con-
trols (Fig. 1a, c). Chondrocyte cloning was also a prominent
feature in the LTP specimens after meniscectomy (Fig. 1d;
asterisk), which is in keeping with the validity of this model's
representation of human OA. The most severe lesions were
Table 1
Primers used for RT-PCR
Gene Annealing temperature (°C) Product size (base pairs) Sequence (5' to 3') GenBank accession number
Collagen II 65 141 F ACGGTGGACGAGGTCTGACT
R GGCCTGTCTCTCCACGTTCA
AF138883
Aggrecan 65 375 F CCGCTATGACGCCATCTGCT
R TGCACGACGAGGTCCTCACT
AF019758
Decorin 55 319 F CAAACTCTTTTGCTTGGGCT
R CACTGGACAACTCGCAGATG
AF125041
Biglycan 65 204 F CCATGCTGAACGATGAGGAA
R CATTATTCTGCAGGTCCAGC
AF034842
Fibromodulin 65 442 F CTGGACCACAACAACCTGAC
R GGATCTTCTGCAGCTGGTTG
AF020291
Lumican 65 284 F CAGCCATGTACTGCGATGAG
R CTGCAGGTCCACCAGAGATT
NM173934
TGF-β 60 271 F CGGCAGCTGTACATTGACTT
R AGCGCACGATCATGTTGGAC
AF000133
CTGF 65 504 F TCTTCTGCGACTTCGGCTCC
R CCTCCAGGTCAGCTTCGCAA
NM174030
Collagen I 65 460 F CCACCAGTCACCTGCGTACA
R GGAGACCACGAGGACCAGAA
AF129287
Collagen III 55 243 F GCTGGCTAGTTGTCGCTCTG
R GTGGGGAAACTGCACAACAT
L47641
GAPDH 55 320 F TCACCATCTTCCAGGAGCGA
R GGCGTGGACAGTGGTCATAA
AF035421
Shown are the details of the primers used for RT-PCR, including annealing temperatures, size of the amplified products, forward (F) and reverse 
(R) sequences, and primer source. CTCG, connective tissue growth factor; GAPDH, glyceraldehyde-3-phosphate dehydrogenase; TGF, 
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confined to the weight-bearing region of the LTP, with signifi-
cant proteoglycan loss and surface fibrillation (Fig. 1e, f).
Histological grading of the meniscectomized and nonoperated
control cartilage specimens confirmed and quantitated the his-
tological observations. In control sheep the modified Mankin
score (mean ± standard deviation) was significantly higher in
the MTP specimens than in the LTP ones (9.3 ± 1.9 versus 3.1
± 1.1; P < 0.01). Following meniscectomy there was a slight
although not statistically significant change in the modified
Mankin score for the MTP specimens (10.7 ± 3.3). The same
could not be said of the LTP specimens, in which meniscec-
tomy resulted in a significant increase from 3.1 ± 1.1 to 23.3
± 1.8 (P < 0.01).
Immunolocalization of types I, II and III collagens
An increase in type I collagen matrix immunostaining was evi-
dent following meniscectomy in the most superficial cartilage
of the LTP specimens (Fig. 2d) and, to a lesser extent, in the
MTP specimens (Fig. 2b), corresponding to areas of degener-
ative change. In nonoperated control sections (Fig. 2a, c), type
I collagen was restricted to the uppermost surface lamina, as
reported previously [29]. Type III collagen, which is typically
seen pericellularly in normal cartilage [30], also exhibited
increased matrix staining after meniscectomy (Fig. 2j, l) com-
pared with nonoperated control (Fig. 2i, k). Type II collagen
was immunolocalized in the matrix throughout the depth of the
cartilage in both MTP and LTP, and there was a generalized
decrease in staining following meniscectomy (Fig. 2e–h). As
expected [31,32], types I and III collagens were also promi-
nently immunolocalized in the marginal osteophytic fibrocarti-
laginous regions in the meniscectomized joints (data not
shown).
RT-PCR
It was not possible to undertake all procedures with some of
the cartilage samples that did not yield at least 1 µg total RNA.
This resulted in four samples being excluded, all from MTP car-
tilage (one from the meniscectomy group and three from the
nonoperated control group). Statistical comparisons of mRNA
levels following meniscectomy as a percentage of control val-
ues were undertaken separately for LTP and MTP cartilages
and are presented graphically in Fig. 3. Following lateral
meniscectomy, mRNA levels in LTP cartilage were found to be
upregulated for the following molecules: aggrecan (1.5 fold; P
< 0.01), type I collagen (11.7-fold; P < 0.01), type II collagen
(3.9-fold; P < 0.01), type III collagen (2.3-fold; P < 0.05), big-
lycan (1.8-fold; P < 0.01) and lumican (14.6-fold; P < 0.01).
In the same region there were downregulations of decorin
(1.6-fold;  P  < 0.01) and CTGF (2.1-fold; P  < 0.05), and
unchanged expression of fibromodulin and TGF-β . In the MTP
cartilage samples, none of the changes in mRNA levels follow-
ing meniscectomy relative to nonoperated controls were sta-
tistically significant.
Western blotting of the small leucine-rich proteoglycans
Western blot analysis of extracts of an equivalent dry weight of
pooled LTP cartilage from control and meniscectomized joints
and OA human cartilage are shown in Fig. 4. There was little
difference in total staining intensity between nonoperated and
meniscectomized cartilage for the 45 kDa intact core protein
of decorin that was also evident in human OA cartilage. Addi-
tional fragmented forms of decorin core protein (32 and 20
kDa) were evident in the cartilage extracts from both the con-
trol and meniscectomy specimens, whereas a 40 kDa
fragment was identified only in meniscectomized cartilage
extracts (Fig. 4; asterisk). Blotting for biglycan identified intact
core protein (43 kDa) and a number of fragments (39, 32, 28
and 26 kDa) in all of the specimens. There was an increase in
staining intensity for all biglycan core protein species in menis-
Figure 1
Histology Histology. Representative histology of medial (a, b) and (c–f) lateral tib-
ial plateau cartilage from nonoperated control (panels a and c) and 
meniscectomized (panels b and d-f) ovine stifle joints. Cell cloning is a 
prominent feature in the lateral tibial plateau following meniscectomy 
(asterisk). Osteophyte formation is evident at the lateral joint margin 
(panel f, arrowheads), and the area of most severe cartilage damage 
with surface fibrillation (rectangle, panel e) and the adjacent area (cir-
cle, panel d) are indicated. Toluidine blue-fast green stain. Scale bar: 
250 µm.Arthritis Research & Therapy    Vol 7 No 4    Young et al.
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cectomized cartilage. The predominant fibromodulin core pro-
tein species identified in all specimens was about 55 kDa in
size, with a slight increase in staining following meniscectomy.
This 55 kDa fibromodulin band is consistent with full-length
core protein [12]. A 28 kDa fibromodulin fragment was
detected only in the extract from meniscectomized joints (Fig.
4; asterisk). Lumican electrophoresed as two predominant
species, a 60–64 kDa band with similar staining intensities
evident in control and meniscectomy extracts. A smaller,
approximately 50 kDa band, which was the predominant spe-
cies in the human OA sample, exhibited greater staining inten-
sity after meniscectomy compared with cartilage from
nonoperated joints. Removal of KS side-chains with keratan-
ase II/endo-β -galactosidase treatment resulted in all of the
lumican migrating at 50 kDa, suggesting that the 60–64 kDa
band represented KS substituted lumican.
Discussion
Our laboratory previously reported biochemical, biomechani-
cal and histological changes that occur in the articular carti-
lage in the ovine lateral meniscectomy model of OA
[22,23,33]. The present study extends these earlier investiga-
tions by examining the expression of a number of important
extracellular matrix components at the mRNA level. One of the
difficulties we encountered was relatively low average RNA
yields (0.85–9.13 µg per 100 mg), which resulted in exclusion
of some MTP samples. Studies utilizing other animal models of
OA have reported RNA yields from 2.5 to 21 µg/100 mg of
normal cartilage [34,35], but the animals used in those studies
(rabbit and canine) were of a much younger age than ours.
Studies using aged human cartilage report much lower aver-
age yields, ranging from 0.669 to 0.839 µg/100 mg of OA and
'normal' cartilage [36]. We attributed the low RNA yield in our
study to our use of an aged population of sheep, although
other factors such as species differences, RNA degradation
and technical factors cannot be excluded. Although we were
able to analyze medial and lateral tibial cartilage separately, the
low yields of RNA from the older sheep precluded further top-
ographical separation. Future studies using younger animals
may permit analysis of affected and unaffected cartilage within
one joint area.
Although morphological and histological changes in cartilage
were most notable in the lateral compartment, changes in the
medial femoro-tibial joint were nevertheless still evident but of
a markedly lesser magnitude, as previously reported [23,37].
In the present study the MTP cartilage in control joints had sig-
nificantly worse histopathological scores than did LTP from
the same joints, which is consistent with age-related change in
the more heavily loaded compartment of these old animals.
The histopathology scores did not increase significantly in the
medial compartment following meniscectomy, and this was
consistent with the lack of change in mRNA levels. Our inabil-
ity to detect differences in mRNA expression in the medial
compartment might have resulted from the small number of
samples evaluated. However, the standard deviation of the
MTP samples was similar to that of the LTP, suggesting that
the lower number of MTPs studied did not contribute to the
lack of statistical significance. Changes in mRNA levels for a
number of molecules were significant in the lateral compart-
ment following meniscectomy. Although our findings are lim-
ited to a single time point following induction of OA, restriction
of significant alterations in gene expression to the LTP indi-
cates that the changes observed were likely associated with
active degradation of cartilage primarily due to altered biome-
chanical forces rather than humoral factors.
Figure 2
Immunolocalisation Immunolocalisation. Immunolocalization of types I (a–d), II (e–h) and III (I–l) collagens in medial (panels a, b, e, f, I and j) and lateral (panels c, d, g, 
h, k and l) tibial plateau cartilage. Sections from representative nonoperated control (panels a, c, e, g, I and k) and meniscectomized (b, d, f, h, j and 
l) joints are shown. Scale bar: 250 µm.Available online http://arthritis-research.com/content/7/4/R852
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In the present study the changes observed in the expression
of aggrecan and type II collagen probably reflect an anabolic
response by the chondrocytes to the altered mechanical
stresses imposed by this surgical procedure, as well as early
OA degeneration. The increase in expression is consistent
with an attempted 'repair' response in early OA, as described
in other animal models [34,35,38]. Levels of mRNA for a par-
ticular molecule may not reflect protein synthesis or its accu-
mulation in tissue, with post-transcriptional regulation and
post-translational processing playing significant roles. Indeed,
we previously demonstrated increased degradation of newly
synthesized aggrecan in cartilage after lateral meniscectomy
in sheep [24]. Furthermore, the changes in mRNA levels
observed in the present study were representative of the entire
MTPs or LTPs and therefore probably included cartilage from
areas with different stages of OA.
In addition to the increase in mRNA for the major cartilage
matrix components aggrecan and type II collagen, significant
increases in expression and protein levels of types I and III col-
lagen were observed following meniscectomy. Type III colla-
gen is present pericellularly in small amounts in normal
articular cartilage [16,30], and type I collagen is is evident in
the most superficial layer [29]. Contrary to early reports [39],
evidence now suggests that both types I and III collagens are
significantly increased in OA cartilage, both at the expression
and protein levels [40,41]. It has been suggested that a major
phenotypic shift occurs in OA toward a de-differentiated
chondrocyte [40]. Interestingly, in the present study we
observed increased amounts of types I and III collagens by
immunohistology in both compartments following meniscec-
tomy, despite increased mRNA levels only being evident in the
lateral compartment. A probable explanation was that the
increased types I and III collagens observed with immunohis-
tochemistry represented the cumulative changes throughout
the course of the disease process while expression levels
reflected chondrocyte metabolism at a specific point in time
(i.e. 6 months following meniscectomy). Changes in collagen
subtypes in pathological cartilage may not only influence the
biomechanical integrity of the tissue but may sequester and
modulate the actions of cytokines, with types I and III collagen
shown to bind oncostatin M specifically [42].
Selective modulation of SLRP mRNA levels in OA cartilage
was observed in the present study, with increased biglycan
and lumican, decreased decorin, and little or no change in
Figure 3
Changes in mRNA levels Changes in mRNA levels. Changes in (a) lateral tibial plateau (LTP) and (b) medial tibial plateau (MTP) cartilage mRNA levels of aggrecan, type I, II, 
and III collagen, decorin, biglycan, fibromodulin, lumican, transforming growth factor (TGF)-β  and connective tissue growth factor (CTGF) following 
lateral meniscectomy (MEN) relative to nonoperated control (NOC) values. Values are expressed as mean ± standard deviation. There were three 
samples for the NOC MTP, six for the NOC LTP, five for the MEN MTP and six for the MEN LTP groups. *P < 0.05, **P < 0.01.Arthritis Research & Therapy    Vol 7 No 4    Young et al.
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fibromodulin. Additionally, we have shown for the first time that
these changes in SLRP expression are confined to the carti-
lage in the compartment undergoing active OA degeneration.
The differential regulation contrasts with the reported increase
in expression of all four SLRPs in late-stage human OA in one
study [19], but it is consistent with another study [43] that
reported no change in decorin but increased biglycan mes-
sage in late stage OA. In the canine anterior cruciate ligament
transection model, increased cartilage mRNA for biglycan,
decorin and fibromodulin have been described [38,44]. The
reported differences in mRNA expression may relate to varia-
ble stages of disease, methods of quantitation and species
evaluated.
The SLRPs have been shown to influence cartilage metabo-
lism indirectly via actions on growth factors such as TGF-β ,
which they inactivate through sequestration and thereby
potentially mitigate its effects in OA [11,45]. Although we
found no change in the expression of TGF-β  following menis-
cectomy, there was a significant decrease in mRNA levels of
CTGF. We speculate that sequestration of TGF-β  by the
SLRPs may have accounted for the decrease in CTGF expres-
sion. Our results contrast with human cartilage, in which an
increase in CTGF in OA was recently reported [46], and this
could be associated with species differences or the stage of
disease. CTGF, a secretory protein involved in fibrotic
response mechanisms in tissues, is an important downstream
effector of TGF-β  [47] and is thought to be involved in promot-
ing the proliferation and/or differentiation of chondrocytes [48-
51]. Further investigation of the specific relationships between
growth factors, collagens and the SLRPs in normal and dis-
eased cartilage is warranted.
Significant proteolysis of the SLRPs was evident in the
present study. SLRP degradation was previously reported in
both human OA [20] and spontaneous canine OA [52], but
not in a canine cruciate ligament transection model of OA [52].
The catabolites that were identified in meniscectomized carti-
lage in the present study were also generally evident in normal
cartilage, indicating similar proteolytic processes in health and
disease. However, in the case of decorin and fibromodulin,
fragments unique to the meniscectomized cartilage were iden-
tified, suggesting the presence of disease-specific proteolytic
processes. In this regard, a specific proteolytic fragment of
fibromodulin was recently identified from interleukin-1 stimu-
lated but not normal cartilage [53]. The cleavage site(s) and
proteinase(s) responsible for extracellular SLRP breakdown in
arthritic cartilage have yet to be identified and are the subject
of further investigation.
A particularly novel finding in the present study was the
increased lumican core protein present in degenerative carti-
lage following meniscectomy, which is consistent with the sig-
nificant increase observed in mRNA levels. Furthermore, the
increased lumican observed by Western blotting was present
in a non-KS substituted form. Limited studies [19,54] have
suggested that lumican primarily exists lacking KS in adult car-
tilage, but cultured chondrocytes have been observed to pro-
duce a KS-substituted form that appeared to be the default
synthesis preference [55]. The catabolic cytokine interleukin-
1β , which may be present in OA joints, stimulates secretion of
lumican deficient in KS [55]. It has been shown that OA
chondrocytes synthesize SLRPs that are differently glyco-
sylated, and that nonglycosylated biglycan and decorin are
more abundant in OA cartilage [20]. Changes in glycosylation
of the SLRPs, whether by altered synthesis or subsequent
Figure 4
Western blot Western blot. Western blot analysis of decorin, biglycan, fibromodulin and lumican in extracts of human osteoarthritis cartilage (OA), nonoperated 
control (NOC) and lateral meniscectomized (MEN) ovine cartilage samples. Core protein fragments of decorin and fibromodulin that were only iden-
tified in MEN are marked with an asterisk. Equivalent amounts of extract from equal dry weights of tissue were loaded per lane following treatment 
with chondroitinase ABC (ChABC). Additionally, Western blot analysis of lumican was performed following treatment with ChABC, endo-β -galactos-
idase (EBG) and keratanase II (KII). The migration positions of prestained protein standards are indicated on the left.Available online http://arthritis-research.com/content/7/4/R852
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degradation, are likely to influence the functional properties of
these molecules in cartilage.
Conclusion
We showed that degradation of cartilage in OA is associated
with significant focal changes in expression and content of
matrix proteins. Accelerated proteolysis of aggrecan and type
II collagen overwhelms the increase in expression of these
major structural proteins. Furthermore, there is a shift in
chondrocyte phenotype, with increased synthesis of collagens
types I and III and a change in the relative levels of the fibril-
associated SLRPs. In particular there is decrease in synthesis
of decorin and an increase in biglycan and lumican, with the
latter lacking KS substitution. It seems likely that the altered
pattern of SLRP synthesis, which is localized to the diseased
joint compartment, along with an increase in SLRP proteolysis,
modifies the biomechanical properties of the matrix and con-
tributes to cartilage breakdown. Changes in SLRP levels could
also significantly modulate the action of potential anabolic fac-
tors such as TGF-β  and its downstream effector CTGF, possi-
bly adding to disease development. An understanding of the
relationship between SLRP metabolism and progressive carti-
lage breakdown in OA may provide both novel diagnostic
markers of disease and therapeutic targets for the treatment of
this disorder.
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